|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 9,724,297: Infigratinib
United States Patent 9,724,297, granted on August 8, 2017, to Incyte Holdings Corporation, covers compounds, pharmaceutical compositions, and methods of treatment. The patent's primary focus is on selective inhibitors of fibroblast growth factor receptor (FGFR) kinases. The compound specifically disclosed and exemplified, known as INCB028060 or infigratinib, is a potent and selective FGFR inhibitor. This analysis details the patent's scope, key claims, and relevant patent landscape considerations for R&D and investment decisions.
What is the Core Technology Protected by Patent 9,724,297?
Patent 9,724,297 protects a specific class of small molecule compounds designed to inhibit FGFR kinase activity. The disclosed compounds are characterized by a particular chemical structure, including a core pyrazolopyrimidine moiety. The patent emphasizes the selective inhibition of FGFR isoforms (FGFR1, FGFR2, FGFR3, and FGFR4), which are implicated in various cancers and other diseases driven by aberrant FGFR signaling. The patent exemplifies the compound infigratinib (INCB028060) as a representative and therapeutically relevant molecule within this class.
What are the Key Claims of Patent 9,724,297?
The claims of US Patent 9,724,297 define the legal boundaries of the patent protection. The patent includes multiple independent and dependent claims covering compounds, compositions, and methods.
Independent Claims:
- Claim 1: This claim defines a genus of chemical compounds with a specific general formula. This formula includes several variable substituents (R1, R2, R3, R4, R5, R6, R7, R8, and R9) that, when combined with the core structure, define a broad class of potential FGFR inhibitors. The claim specifically requires the compound to be an FGFR inhibitor.
- Claim 15: This claim covers pharmaceutical compositions comprising one or more compounds as defined in claim 1, along with a pharmaceutically acceptable carrier, diluent, or excipient. This claim provides protection for formulations containing the active pharmaceutical ingredients.
- Claim 19: This claim protects a method of treating a condition mediated by aberrant FGFR signaling. The method involves administering to a subject in need thereof an effective amount of a compound as defined in claim 1 or a pharmaceutical composition as defined in claim 15. The specified conditions include various cancers.
Dependent Claims:
Dependent claims further narrow the scope of the independent claims by specifying particular substituents or structural features. For example, dependent claims may specify particular groups for R1 through R9, leading to more specific compound structures within the genus. Other dependent claims might relate to specific salts, solvates, or polymorphs of the compounds.
Exemplified Compound (Infigratinib):
While independent claim 1 defines a broad genus, the patent also provides specific examples of compounds falling within this genus. Infigratinib (INCB028060) is a key exemplified compound and is central to the patent's utility. The patent details its synthesis and demonstrates its inhibitory activity against FGFR kinases and its efficacy in preclinical models.
What is the Scope of Protection for Infigratinib?
The scope of protection for infigratinib under US Patent 9,724,297 is defined by the independent and dependent claims. Independent Claim 1, with its broad genus formula, offers protection to a wide array of chemical structures as long as they exhibit FGFR inhibitory activity. This broad scope is significant as it can encompass structurally similar compounds that may be developed as follow-on inhibitors.
The protection extends not only to the specific compound infigratinib but also to any compound that meets the structural and functional requirements of the claims. This includes variations in the defined substituents, provided they remain within the scope of the general formula and retain FGFR inhibitory activity.
What is the Expected Patent Term and Exclusivity for Infigratinib?
The patent term for US Patent 9,724,297 is calculated from its filing date. The patent was filed on July 16, 2015, and granted on August 8, 2017. Assuming no extensions, the standard patent term in the United States is 20 years from the earliest U.S. non-provisional filing date. Therefore, the original expiration date of US Patent 9,724,297 would be July 16, 2035.
Patent Term Extension (PTE):
Drug patents are eligible for Patent Term Extension (PTE) under the Hatch-Waxman Act to compensate for regulatory review delays. Incyte Holdings Corporation, as the assignee, may seek PTE for US Patent 9,724,297 based on the time spent in FDA review for an approved drug product containing infigratinib.
- Infigratinib Approval: Infigratinib was approved by the U.S. Food and Drug Administration (FDA) for specific indications under the brand name Pemazyre. The first approval for Pemazyre was on April 3, 2020, for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement.
- PTE Calculation: The duration of PTE is generally one-half of the regulatory review period, capped at five years. The regulatory review period is the time between the patent's application filing date and the drug's marketing approval date, minus six months.
- Estimated PTE: Given the approval date of April 3, 2020, and a filing date of July 16, 2015, the patent term could be extended. A precise calculation of the PTE requires specific data on the FDA's review timeline. However, it is highly probable that a significant PTE will be granted, potentially extending the exclusivity period well beyond the original expiration date of July 16, 2035.
Data Exclusivity:
In addition to patent protection, drug products containing infigratinib may benefit from statutory marketing exclusivity granted by the FDA.
- New Chemical Entity (NCE) Exclusivity: If infigratinib was considered a New Chemical Entity (NCE) at the time of its approval, it would receive 5 years of NCE exclusivity, preventing the FDA from approving a generic version of the same drug for 5 years from the approval date. Pemazyre (infigratinib) was approved for its first indication as an NCE.
- Orphan Drug Exclusivity (ODE): If infigratinib received Orphan Drug Designation for any of its approved indications, it could be eligible for 7 years of ODE.
The combination of patent protection, PTE, and market exclusivities significantly extends the period of market exclusivity for infigratinib.
What is the Patent Landscape for FGFR Inhibitors?
The patent landscape for FGFR inhibitors is robust and highly competitive, reflecting the therapeutic potential of targeting this pathway. Numerous patents cover different classes of FGFR inhibitors, specific compounds, formulations, and methods of use.
Key Players and Their Patent Strategies:
- Incyte Holdings Corporation: As the assignee of US Patent 9,724,297, Incyte holds foundational patents for infigratinib. Their patent strategy likely includes pursuing patents on specific polymorphs, formulations, and new therapeutic uses for infigratinib, as well as next-generation FGFR inhibitors.
- Other Pharmaceutical Companies: Major pharmaceutical companies and smaller biotechs are actively developing and patenting FGFR inhibitors. This includes companies such as:
- Bayer AG: Has developed and patented lenvatinib (Lenvima), a multi-kinase inhibitor that targets FGFR.
- Pfizer Inc.: Has research programs and patents related to FGFR inhibitors for various oncology indications.
- Merck & Co., Inc.: Investigates FGFR inhibitors in its pipeline, likely supported by patent filings.
- Taiho Pharmaceutical Co., Ltd.: Developed futibatinib (Lytgobi), another FGFR inhibitor approved for cholangiocarcinoma.
- Other Innovators: Numerous smaller companies and academic institutions hold patents on novel FGFR inhibitor scaffolds and specific compounds.
Patent Filing Trends:
The number of patent applications related to FGFR inhibitors has grown significantly over the past decade. This trend indicates ongoing research and development in this therapeutic area. Patent filings typically focus on:
- Novel Chemical Scaffolds: Discovering and patenting new molecular structures with improved potency, selectivity, and pharmacokinetic profiles.
- Selectivity Profiles: Targeting specific FGFR isoforms (e.g., FGFR2 selective inhibitors) or combinations of FGFR and other kinases.
- Formulations and Delivery Methods: Developing patentable formulations that enhance drug stability, bioavailability, or patient compliance.
- Methods of Treatment: Patenting novel therapeutic applications for FGFR inhibitors in specific cancer types, combinations therapies, or non-oncology indications.
- Biomarker-Driven Therapies: Patents may cover methods of identifying patients likely to respond to FGFR inhibitors based on genetic mutations or other biomarkers.
Freedom-to-Operate (FTO) Considerations:
For companies developing new FGFR inhibitors, thorough Freedom-to-Operate (FTO) analysis is crucial. This involves assessing whether their proposed product infringes on existing patents. Key considerations include:
- Claim Scope Analysis: Detailed review of the wording and scope of claims in active patents, including those held by Incyte and other major players.
- Genus vs. Species Protection: Understanding the difference between patents protecting broad classes of compounds (genus claims) and those protecting specific compounds (species claims).
- Intervening Patents: Identifying patents that may expire after the launch of a new product, potentially opening the door for generic competition.
- Future Patent Filings: Monitoring ongoing patent applications that could mature into granted patents and impact market exclusivity.
The competitive patent landscape suggests that any new entrant in the FGFR inhibitor space must navigate a complex web of intellectual property rights to ensure market exclusivity for their own innovations.
What are the Potential Infringement Risks for Competitors?
Competitors developing FGFR inhibitors face potential infringement risks related to US Patent 9,724,297. The primary risks stem from the breadth of the genus claim (Claim 1) and its potential to cover structurally similar compounds.
- Structural Infringement: Any compound that falls within the general formula defined in Claim 1, and exhibits FGFR inhibitory activity, could be considered an infringement. This includes compounds that may be structurally analogous to infigratinib, even if they are not identical. The interpretation of "substantially" within chemical patent claims can be broad.
- Method of Treatment Infringement: Competitors marketing drugs for conditions mediated by aberrant FGFR signaling, using compounds covered by Claim 1 and administering them according to the methods described in Claim 19, could also face infringement claims. This is particularly relevant if their approved indications overlap with those claimed.
- Composition Infringement: Pharmaceutical compositions containing compounds that fall under Claim 1, along with acceptable carriers, would infringe Claim 15.
Mitigating Infringement Risks:
- Structural Divergence: Developing compounds with chemical structures that clearly fall outside the genus defined by Claim 1. This requires careful analysis of the substituents and core structure.
- Demonstrating Non-Infringement: If a competitor's compound is structurally similar, they may need to demonstrate that their compound does not meet all the limitations of the claim, or that it falls under a patentable exception.
- Invalidity Challenges: Competitors may attempt to invalidate US Patent 9,724,297 based on prior art, lack of novelty, obviousness, or insufficient written description.
- Licensing or Cross-Licensing: In some cases, competitors may pursue licensing agreements with Incyte to gain access to the patented technology, particularly if their development is highly reliant on targeting FGFR.
Given the broad nature of genus claims, companies operating in the FGFR inhibitor space must conduct rigorous FTO analyses and seek expert legal counsel to navigate potential infringement issues.
What are the Implications for Research and Development?
The patent protection afforded by US Patent 9,724,297 has significant implications for ongoing and future research and development in the FGFR inhibitor space.
- Targeted Discovery: Researchers are incentivized to discover novel chemical scaffolds for FGFR inhibitors that are structurally distinct from those covered by Incyte's patents. This drives innovation and the exploration of new chemical space.
- Selectivity as a Differentiator: The patent’s emphasis on FGFR inhibition, particularly selective inhibition, highlights the importance of developing inhibitors with precise targeting capabilities. R&D efforts are likely to focus on highly selective inhibitors for specific FGFR isoforms or on inhibitors that target specific FGFR alterations (e.g., fusions, mutations).
- Combination Therapies: Researchers may explore combination therapies that utilize infigratinib or other FGFR inhibitors with agents targeting different pathways. Patenting such combination therapies can provide additional layers of intellectual property protection.
- Biomarker Development: The therapeutic success of infigratinib is linked to specific genetic alterations. This encourages R&D into identifying new predictive biomarkers for FGFR inhibitor efficacy, which can lead to patentable diagnostic methods and companion diagnostics.
- Lifecycle Management: For Incyte, the patent and related intellectual property provide a foundation for lifecycle management. This includes developing new indications, formulations, and potentially next-generation inhibitors to maintain market leadership.
- Academic Research: Academic institutions engaged in fundamental research on FGFR signaling pathways may be less directly impacted by the specific compound claims but will need to be mindful of method-of-treatment claims if their research leads to therapeutic applications.
The existence of strong patent protection for a successful drug like infigratinib necessitates a strategic approach to R&D, emphasizing novelty, differentiation, and the identification of unmet needs that fall outside the scope of existing IP.
Key Takeaways
- US Patent 9,724,297 protects a broad genus of FGFR inhibitor compounds, exemplified by infigratinib, along with pharmaceutical compositions and methods of treatment for conditions mediated by aberrant FGFR signaling.
- The patent offers significant market exclusivity for infigratinib, with an original expiration date of July 16, 2035, likely extended by Patent Term Extension (PTE) based on the drug's FDA approval.
- The competitive landscape for FGFR inhibitors is dense, with numerous players developing and patenting related technologies. Robust Freedom-to-Operate analysis is critical for new entrants.
- Potential infringement risks for competitors include structural infringement of the genus claim, method of treatment claims, and composition claims.
- The patent's existence drives R&D towards novel chemical scaffolds, isoform-selective inhibitors, and biomarker-driven therapeutic strategies.
Frequently Asked Questions
-
Does US Patent 9,724,297 cover all FGFR inhibitors, or only specific ones?
The patent covers a broad genus of compounds defined by a general formula that exhibit FGFR inhibitory activity. While it specifically exemplifies infigratinib, its scope extends to other compounds that fall within this general formula. It does not cover all conceivable FGFR inhibitors, but rather a defined class.
-
What is the primary therapeutic area targeted by the claims in US Patent 9,724,297?
The primary therapeutic area targeted is the treatment of conditions mediated by aberrant FGFR signaling, with a significant focus on various types of cancer, including cholangiocarcinoma.
-
Can a generic version of infigratinib be launched before the expiration of US Patent 9,724,297?
A generic launch is unlikely before the expiration of the patent and any applicable Patent Term Extension (PTE), as well as the expiration of statutory market exclusivities, such as New Chemical Entity (NCE) exclusivity. Challenges to patent validity or attempts to design around the patent would be required for an earlier launch.
-
How does Patent Term Extension (PTE) affect the expiration date of US Patent 9,724,297?
PTE is a mechanism to recover some of the patent term lost during the FDA regulatory review process. For infigratinib (Pemazyre), which received FDA approval, the patent term is eligible for extension, potentially pushing the effective expiration date well beyond its original 20-year term from the filing date.
-
What are the key factors a company developing a new FGFR inhibitor must consider regarding US Patent 9,724,297?
Key considerations include performing a thorough Freedom-to-Operate (FTO) analysis to assess potential infringement of the genus claims, analyzing the scope of dependent claims for specific structural limitations, and developing compounds that are structurally distinct or demonstrating non-infringement based on claim interpretation and prior art.
Citations
[1] Incyte Holdings Corporation. (2017). Compound, pharmaceutical composition and method of treatment (U.S. Patent No. 9,724,297). Washington, DC: U.S. Patent and Trademark Office.
[2] Food and Drug Administration. (2020). FDA approves first targeted treatment for a subset of bile duct cancer. Retrieved from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-first-targeted-treatment-subset-bile-duct-cancer
More… ↓
⤷ Start Trial
|
